Drug Trial Radar · NCT06993844
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
233
Planned (sponsor's estimate)
Start
Jun 10, 2025
Primary completion
Jun 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Ensem TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Conditions
- Advanced Solid Tumors
- Advanced Breast Cancer
Interventions
ETX-636 dose escalationDrug
ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet that will be taken once per day in 28-day cycles, to evaluate escalating dose levels.
ETX-636 dose escalation in combination with fulvestrantDrug
ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to evaluate escalating dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.
ETX-636 dose expansion in combination with fulvestrantDrug
ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to expand selected dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate Safety and Tolerability of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part BTime frame: First 28 days of treatment
- Evaluate Safety and Tolerability of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part BTime frame: Average of 6 months
- Select the Recommended Phase 2 Dose(s) (RP2D) in Part B to be further explored in Part C (combination therapy expansion)Time frame: Average of 6 months
- Evaluate efficacy of ETX-636 plus fulvestrant combination therapy at the RP2D(s) in Part CTime frame: Average of 6 months
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Recruiting
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Yale University, Yale Cancer Center
New Haven, Connecticut · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Carolina BioOncology Institute
Huntersville, North Carolina · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
START
San Antonio, Texas · Recruiting
NEXT
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Beijing Luhe Hospital,Capital Medical University
Beijing, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
Shandong Cancer Hospital&Institute
Shandong, China · Recruiting
Fudan University Shanghai Cancer Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.